Should You Buy Erytech Pharma Shares in 2026?

Buying Erytech Pharma stock is a smart move for any investor looking to invest in biotechnology/biopharmaceutical stocks. This stock boasts strong financial health and a promising future. It also has numerous therapies in the final stages of clinical trials and many products in the commercialization phase, which could positively impact Erytech Pharma's share price. If you're interested in this stock, here's our comprehensive guide to investing in Erytech Pharma.

How to Buy Erytech Pharma Stock on the Stock Exchange?

1. Find a broker to buy shares on the stock market – DEGIRO.
2. Create an account and verify it.
3. Deposit funds into their account.
4. Search for Erytech Pharma (ERYP) stock from the broker's platform, click on it and place a buy order.

Best Stock Broker to Buy Erytech Pharma Stocks

Should You Buy Erytech Pharma Stock: Is It the Right Time to Invest in Erytech Pharma?

Yes. Here's why it's a good time to look how to buy stocks Erytech Pharma and actually buy them:

• Erytech Pharma performed well during the third quarter of 2025. The company's stock rose by +12,99%.
• The company has several cancer treatments in the commercialization phase.
• Erytech Pharma operates in the biotechnology sector, a promising sector that attracts many investors who wish to support research in the medical field.
• The company has a stable cash flow above the average for other companies in the biotechnology sector in France.
• Erytech Pharma has a significant market capitalization estimated at around 64 million euros.
• This company has recorded a marked increase in its net income since 2020.
• The forecast for net earnings per share (EPS) of Erytech Pharma shares indicates an increase for the next two years (2025 and 2025).

Should you buy Erytech Pharma stock or sell in 2026?

It is recommended to buy Erytech Pharma shares in 2025, here is why:

• The group's general sales have been on the rise since 2017.
• The company has recorded markedly improved results since 2020. Erytech Pharma is recovering, despite its many previous negative results.
• Erytech Pharma is an innovative company in the biotechnology sector that works to fight cancer.
• The company has obtained patents on therapies against pancreatic cancer, patents that promise better financial results for the next few years.
• Erytech Pharma has several therapies in the marketing phase. This also suggests better financial results for the future.

Should You Buy Erytech Pharma Stock: Quote and Real-Time Erytech Pharma Share Price

Should You Buy Erytech Pharma Stock: Which Broker is Recommended to Buy Erytech Pharma Stock?

For buy Biotech shares like Erytech Pharma stock, we recommend the broker DEGIRO. Here's why :

• Very low fees on the purchase of Erytech Pharma shares
• Secure, ergonomic and award-winning platform
• Transparent pricing
• No minimum amount required as deposit
• Available and efficient customer service

Should You Buy Erytech Pharma Stock: Market Capitalization & Key Figures of Erytech Pharma Stock

When Should You Buy Erytech Pharma Stock?

Erytech Pharma is one of the health stocks to buy now for the following reasons:

• An expected increase in turnover in the coming years. Analyst forecasts point to a likely 486% increase in revenue.
• Green indicators for Erytech Pharma shares, with expected growth in net earnings per share, EBIT and the company's share price.
• Positive news from the Erytech Pharma SA group During the third quarter of 2025, the company received “Fast Track” designation from the US FDA for hypersensitive ALL therapy.
• Therapies already in the commercialization phase.

Why Invest in the Erytech Pharma Share (ISIN Code = FR0011471135)?

• Strong market capitalization estimated at nearly 64 million euros.
• More than a decade of experience in the biotechnology sector. It was in 2004 that the Erytech Pharma group was founded.
• Company focused on innovation. Erytech Pharma has focused its development strategy on research and innovation. It develops innovative therapies to fight cancer.
• Significant visibility and credibility with institutional investors.
• Several clinical trials in the marketing phase.
• Many therapies in final stages of clinical trials.

Buying Erytech Pharma Share – It's Investing in the Biotechnology Business

• The biotechnology sector weighs more than 1 billion dollars on the stock exchange, with more than 000 listed companies.
• Europe has more than 150 listed companies in this sector, which corresponds to 13% of the sector's global market capitalization. France ranks eighth in the world in terms of listed companies in the world, with 4,2% of listed biotechs.
• There is also an increase in financial results for the sector as a whole. Moody's forecasts a 4% to 6% increase in turnover in 2025.
• The biotechnology sector is a promising sector with great diversification. Companies in the sector are developing innovative treatments to fight cancers, tumors and other pathologies.
• Erytech Pharma SA, in its development strategy, relies on signing partnerships with other companies in the same sector.
• Due to the nature of their business, most biopharmaceutical companies achieve loss-making results during the research phase. However, if the clinical trials are successful, the commercialization of the treatment allows the company to offset its losses and generate profits.
• The secret to the viability of companies in the sector lies in the stability of their cash flow. Erytech Pharma has significant cash, which enables it to ensure the continuity of its activities.

With Which Stock Exchange Products Should I Buy Erytech Pharma Shares?

• Erytech Pharma shares for cash, through the broker DEGIRO.
• Erytech Pharma share CFDs, available from CFD brokers.
• ETFs integrating Erytech Pharma, ETFs accessible through the broker DEGIRO.
• Stock market indices where the Erytech Pharma title appears, indices accessible from the broker DEGIRO.

Should You Buy Erytech Pharma Stock: Erytech Pharma Stock Price Prediction

Should You Buy Erytech Pharma Stock: Erytech Pharma Share Price Analysis

Analysis 1: In its development strategy, Erytech Pharma SA relies on signing partnerships with companies in the same sector. It is therefore important to keep an eye on ERYTECH's news.

Analysis 2: Listed at the Paris stock exchange, Erytech Pharma SA must constantly obtain information relating to clinical trials resulting from the research of other companies in the same sector. This strategy can enable the company to seize new opportunities.

Analysis 3: Erytech Pharma could also venture into new areas of medical research. The company's drive to innovate and technological potential could help Erytech Pharma seize new opportunities.

Analysis 4: The results of the group's clinical trials, as well as the performance of cancer therapies, may influence Erytech's share price.

Analysis 5: Positive news for the company could increase its share price. Conversely, the failure of clinical trials could cause Erytech Pharma's share price to fall.

Fundamental Analysis – Should You Buy Erytech Pharma Stock This Month?

Yes, fundamental analysis on this stock and its company leads to the conclusion that you should buy Erytech Pharma stock now. Here are some of those analyses:

• Erytech Pharma is one of the leaders in biotechnology in France and in Europe. This company competes with other names such as Adocia (Buy Adocia Stock).
• The company has a significant market capitalization of around 64 MEUR.
• Erytech Pharma conducts research into new segments of the medical field.
• The success of clinical trials and the obtaining of patents will have a positive impact on the Erytech Pharma share price.
• Erytech Pharma SA's growth indicators are green: forecasts of the company's turnover and operating results are on an upward trend.
• Signing new partnerships with companies in the same sector could lead to better clinical results for ERYTECH.

Technical Analysis – Should You Buy Erytech Pharma Stock Right Now?

Yes, at the time of writing this guide several indicators are favorable to the purchase of Erytech Pharma stock:

• The RSI (Relative Strength Index) of the Erytech Pharma share is around 97%. This shows that the trading volume of Erytech Pharma shares is high at the moment. In addition, the share price could experience an upward trend in the coming days.
• The support line favors the purchase of Erytech Pharma stock. Investors can buy Erytech Pharma Group shares at this time to take advantage of the future rise in the share price.
• Bollinger Bands analysis shows that Erytech Pharma stock price is showing a strong downtrend at the moment. This is a favorable signal to buy this stock.
• The moving averages are certainly higher than the current price of the Erytech Pharma share, but the company's results have recorded a significant increase over the course of the last three quarters.

Should You Invest in Erytech Pharma: Elements in Favor of a Rising Share Price Erytech Pharma

• Erytech Pharma benefits from subsidies granted by the French State.
• The company's development strategy is realistic. It is based on signing new partnerships with companies in the same sector and directing research towards new segments of medical research.
• The biotechnology sector worldwide is performing well, with an estimated market capitalization of over $1 trillion.
• Erytech Pharma has recorded an increase in its turnover over the past three years. Expert forecasts predict an increase in turnover in the entire sector for the next few years.
• The company's research areas are focused on the development of therapies against cancer, orphan diseases and immunotherapy.
• The success of terminal clinical trials is a positive sign of the company's future profitability.

Should You Buy Erytech Pharma Stock or Innate Pharma Stock

Should we Buy Erytech Pharma Share: does Erytech Pharma have a future?

Yes, Erytech Pharma has a bright future. Here are the elements that justify this promising future of this company:

• The biotechnology sector brings many opportunities for companies in the sector that stand out, such as Erytech Pharma. The market cap of the entire industry is worth over $1 trillion.
• The forecasts announce a future increase in the turnover in the whole sector.
• Erytech Pharma SA has recently obtained several patents during the year 2025. In November 2025 for example, Erytech Pharma obtained a US patent for the use of Methioninase and Asparaginase in the treatment of solid tumors.
• The company's recent financial results show a marked improvement in the company's performance.
• Growth indicators could register an increase in the coming years. EBITDA could increase from -60,6 (2025) to up to 2,00 in 2025.
• Erytech Pharma operates in an innovative sector. It develops innovative therapies against various forms of cancer.
• The company is listed on Euronext and Nasdaq, which increases the visibility and credibility of the company with institutional investors.

Should You Buy Erytech Pharma Stock: Erytech Pharma's Business Model

• Field of activity: Biopharmaceuticals, Biotechnology
• Avantagecompetitive challenges: Development of innovative cancer therapies.
• Value creation: marketing of products and services; royalties on sales of patents for therapies against cancers and orphan diseases.
• Main segments: biotechnology, immunotherapy, rare diseases.

Should You Buy Erytech Pharma Share: Who are the Investors in Erytech Pharma Share – Shareholding?

Should You Buy Erytech Pharma Action: Who are Erytech Pharma's Partners?

• New York Blood. To improve davantage its clinical studies of innovative therapies by encapsulation of drugs in red blood cells, Erytech Pharma has been collaborating for several years with the company New York Blood. New York Blood is also a world-renowned biopharmaceutical company.
• Since 2018, Erytech Pharma has been collaborating with Oncodesign, a company specializing in the biopharmaceutical field. This collaboration aims to develop innovative treatments against new forms of cancer.

Should You Buy Erytech Pharma Stock: Who Are Erytech Pharma's Competitors?

• Transgene is a French biopharmaceutical company specializing in the development of therapeutic vaccines. It is one of Erytech Pharma's main competitors in France.
• BristolMyersSuibb is a competitor of the Erytech Pharma SA group. It is one of the first companies to focus its research on the fight against cancer. BristolMyersSuibb has developed a treatment for lung cancer and collaborates with Merck Laboratories.
• Innate Pharma – Buy Innate Pharma stock -. This French company develops treatments against cancer and vaccines against several pathologies. Innate Pharma also collaborates with giants of the pharmaceutical industry such as:
  • AstraZeneca - Buy Astra Zeneca shares
  • BMS

Should You Buy Erytech Pharma Stock: History & Journey of Erytech Pharma

• 2004: creation of Erytech Pharma SA by Yann Godfrin and Pierre-Olivier Goineau;
• 2010: Yann Godfrin becomes Scientific Director of Erytech Pharma.
• 2011: Erytech Pharma SA joins forces with the Teva group, an Israeli company in the biopharmaceutical field.
• 2013: first Erytech listing on Euronext
• 2015: Erytech Pharma SA fails its listing on NASDAQ
• 2016: Yann Godfrin resigns from his position as Scientific Director
• 2017: Erytech Pharma SA joins the NASDAQ index for a first listing on the New York Stock Exchange
• 2019: In October, Erytech files a marketing application for the drug Graspa with the European Medicines Agency.
• 2019: Erytech Pharma continues its clinical trials on acute myelogenous leukemia (AML).
• 2020: Erytech Pharma obtains 60 million euros in funding for phase 3 of its clinical study.
• 2025: Erytech Pharma obtains Fast Track certification from the US FDA
• 2025: Erytech Pharma records €46,3 million in net cash as of June 30, 2025
• May 2025: Erytech Pharma announces that it has reduced its quarterly loss to €11,9 million
• April 2025: RA Capital Healthcare Fund sells part of its Erytech Pharma shares on the market.

Should You Buy Erytech Pharma Share: Is Stock Market Investment on Erytech Pharma Promising?

Yes. Here is why you should invest in Erytech Pharma:

• Erytech Pharma is a pharmaceutical company evolving in a sector of the future.
• The company holds numerous patents which entitle it to royalties on the sales of operators. These royalties can reach up to 50% of sales.
• Erytech Pharma is listed on Euronext and NASDAQ, which gives it greater credibility and greater visibility.
• The company develops innovative solutions to fight various forms of cancer.
• New opportunities are offered to the company with the conquest of new research segments.
• The recent success of the group's clinical trials suggests better performance for the days to come.
• Erytech Pharma already has several therapies in the marketing phase.
• Erytech's collaboration with many companies in the biotechnology sector suggests better clinical results and the development of innovative therapies against orphan diseases and cancers.

Tips for Investing Well in Erytech Pharma Stocks

• Carefully examine the company's cash flow. Pharmaceutical companies need substantial cash reserves to ensure their long-term viability.
• Consider the company's clinical results. Treatments in the commercialization phase allow the company to generate profits. The more treatments the company has in the commercialization phase, the more profits it can generate in the short term.
• Define an investment budget and set realistic objectives before committing. The amount to invest in Erytech Pharma shares should be determined by considering several factors (risks, potential return, financial capacity, etc.), and profit targets should be realistic, taking into account that the return is more substantial over the long term with this type of investment.
• Invest with a reliable stockbroker. This broker should also be secure and have a good reputation, charge minimal fees, and offer a user-friendly investment platform. We highly recommend DEGIRO.
• Follow the news about Erytech Pharma. It (the news about the company) helps you to some extent to make investment (or divestment) decisions regarding this stock.
• Consider expert analyses and opinions on the company and stock Erytech Pharma, especially when you are not yet familiar with this company/stock or when you are new to stock market/share investing.
• Conduct a technical and fundamental analysis of the company and the Erytech Pharma stock. This will help mitigate certain risks and identify the best investment opportunities in this stock.

Should you buy Erytech Pharma shares?

Yes. Erytech Pharma has a promising future, thanks in particular to its extensive experience in the biopharmaceutical and biotechnology sectors, its numerous clinical trials in the terminal experimental phase, its numerous therapies in the marketing phase, its satisfactory financial results (current and future) and rising, or even its large cash position.

Is Erytech Pharma operating in a promising sector?

Yes. The biotech sector alone has a market capitalization of over $1000 trillion. According to Moody's, the turnover of the entire sector could experience an increase of nearly 486% in the coming years. Several performance indicators (net results, turnover, EBITDA) are green for the next three years in this sector.

What is the Erytech Pharma share price?

The Erytech Pharma share price is €2,325 at the time of writing this guide.